A Groundbreaking New Platform for Targeted Drug Discovery

ThirdLaw Molecular LLC has pioneered the development of Spiroligomer™ molecules and is developing this innovative, patent-protected, therapeutic modality into a new class of more targeted medicines. The mission of the Company is to create a revolutionary category of molecules that transform how diseases are diagnosed and treated – more safely and effectively.

Spiroligomer™ Molecules – Reimagining Peptides

We have developed a novel chemical platform of synthetic, modular, fused-ring structures with a diverse range of functional groups, allowing us exquisite control of their molecular shapes. Using this platform, ThirdLaw Molecular is designing and synthesizing libraries of billions of unique, elegantly structured, chemically diverse compounds for highly selective binding of proteins of biologic interest.

Spiroligomer™ Molecules as Therapeutics

The highly structured nature of Spiroligomer™ molecules allows for carefully selected functional groups to be deliberately presented to target proteins for highly selective binding. This capability, along with their stability, cell permeability, protease resistance, non-immunogenicity, and potential oral bioavailability, make Spiroligomer™ molecules an excellent source of effective therapeutics with limited off-target effects. Coupled with the computational design capabilities being developed by ThirdLaw Molecular, Spiroligomer™ technology represents an innovative platform for targeted drug discovery.

Spiroligomer™ Molecules as Therapeutics

The highly structured nature of Spiroligomer™ molecules allows for carefully selected functional groups to be deliberately presented to target proteins for highly selective binding. This capability, along with their stability, cell permeability, protease resistance, non-immunogenicity, and potential oral bioavailability, make Spiroligomer™ molecules an excellent source of effective therapeutics with limited off-target effects. Coupled with the computational design capabilities being developed by ThirdLaw Molecular, Spiroligomer™ technology represents an innovative platform for targeted drug discovery.

Transforming
Diagnostic Testing

Spiroligomer™ molecules are monoclonal antibody-like in their ability to selectively bind to target proteins, with a clear application in diagnostic testing. They are synthetic, highly stable molecules, that are affordable to develop and manufacture, without the batch-to-batch variability that affects performance. The platform offers a revolutionary approach to the development of diagnostics.

ThirdLaw Molecular LLC was founded in 2020 by Christian Schafmeister, Ph.D., Professor of Chemistry at Temple University, to advance his research into synthetic alternatives to proteins and develop an entirely new platform for targeted drug discovery. He is joined by a team of passionate innovators in pursuit of this mission.

The most basic principle of molecular biology is that structure defines function. This is our inspiration as we design libraries of Spiroligomer™ molecules as a source of effective and safer therapeutics and diagnostics.

– Christian Schafmeister